Short Report

Oncogene (2005) 24, 3836−3841. doi: 10.1038/sj.onc.1208535 Published online 14 March 2005
Published online 14 March 2005

Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation

Daniele Bergamaschi1, Yardena Samuels1, Shan Zhong1 and Xin Lu1

  1. 1Ludwig Institute for Cancer Research, University College London, 91 Riding House Street, London W1W 7BS, UK

Correspondence: X Lu, University College London, Ludwig Institute for Cancer Research, Courtauld Building, 91 Riding House Street, London W1W 7BS, UK. E-mail: [email protected]

Received 18 June 2004; Revised 10 December 2004; Accepted 17 January 2005; Published online 14 March 2005.



Using various mutants of p53 and mdm2, we demonstrate here that both the DNA binding and transactivation function of p53 are required for ASPP1 and ASPP2 to stimulate the apoptotic functions of p53. Mdm2 and mdmx prevent ASPP1 and ASPP2 from stimulating the apoptotic function of p53 by binding and inhibiting the transcriptional activity of p53. Importantly, mdm2 and mdmx can prevent the stimulatory effects of ASPP1 and ASPP2 without targeting p53 for degradation. These data provide a novel mechanism by which mdm2 and mdmx act as potent inhibitors of p53.


ASPP, p53, mdm2, mdmX, apoptosis, transactivation

Extra navigation